Merck & Co. Pays US$35 M Upfront for Kelun-Biotech’s ADC Oncology Drug
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)
Published: 29 Jul-2022
DOI: 10.3833/pdr.v2022.i7.2710 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In another effort to bolster its oncology portfolio, Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS